B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG (FRA:DE000520) EQS-Adhoc: BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties
Transparency directive : regulatory news
|
EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties Zwingenberg, Germany, 31 October 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) signed an exclusive technology pharma licensing agreement with Akribion Therapeutics GmbH (“Akribion”) for its genome editing uclease G-dase E®. In exchange for granting exclusivity for pharma applications to Akribion, BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees. In addition, the company will be entitled to royalties on net sales. The payment structure is based on clinical development progress and market success of Akribion. Akribion is independently owned from the Company and seed financed by venture capital. Non-Pharma related proprietary CRISPR rights remain with BRAIN for commercialization in its core business. This transaction remains subject to customary closing conditions.
Notifying person: Martina Schuster BRAIN Biotech AG – Investor Relations – Darmstädter Str. 34-36 64673 Zwingenberg Deutschland www.brain-biotech.com Investor Relations Office Tel.: +49-(0)-6251-9331-0 Fax: +49-(0)-6251-9331-11 E-Mail: ir@brain-biotech.com IMPORTANT NOTICE This announcement may not be published, distributed or released in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia), Australia, Canada, Japan or any other jurisdiction in which the publication, distribution or release would be unlawful. This announcement does not constitute an offer of securities of the company for sale or a solicitation of an offer to purchase securities of the company. There will be no public offer of securities of the Company. End of Inside Information
31-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2020423 |
| End of Announcement | EQS News Service |
|
|
2020423 31-Oct-2024 CET/CEST
source : webdisclosure.com